Yesterday, the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously in favor of approving Novartis’ AIN457 (secukinumab) for moderate-to-severe plaque psoriasis.
Yesterday, the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) voted unanimously in favor of approving Novartis’ AIN457 (secukinumab) for moderate-to-severe plaque psoriasis. The materials for this meeting can be found HERE.
DODAC voted 7-0 in favor of secukinumab, a selective interleukin-17A inhibitor, based on 10 Phase II/III clinical studies which included nearly 4,000 patients. The studies showed that treatment with secukinumab resulted in high rates of clear to almost clear skin at week 12 and it has shown superiority to Amgen’s Enbrel (etanercept), an anti-TNF standard of care.
Currently, the most common treatment option for individuals suffering from psoriasis are injectable therapies that inhibit tumor necrosis factor (TNF); however, Novartis emphasized a survey by the National Psoriasis Foundation in which over half of patients with psoriasis are still dissatisfied with their disease management.
Vas Narasimhan, Novartis Global Head of Development, stated that “there is a need for novel therapies, as not all treatments are appropriate or effective in every patient.” He added, “..the advisory committee decision brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis.”
The FDA is not bound by its panel’s recommendations; however, they normally take them into consideration. If approved, secukinumab will be the first IL-17A inhibitor on the market. A final decision is expected by early 2015.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact email@example.com.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us